Sobi’s strategy is based on our vision of becoming a global leader in getting transformational treatments to people with rare diseases. We continue to invest in our strongly growing market position in haemophilia. Having seen the transformative benefits of our extended half-life treatments for people with haemophilia A and B, enabling access for more people through their local healthcare systems is a moral imperative. The dramatic commercial growth in this area is also generating significant revenue, allowing us to invest further in the haemophilia space.
Enlarging our Immunology portfolio allows us to create a better balance for our overall business operations, while ensuring sustainable growth in both the short and long term.
Major expansion in North America, combined with continued growth in our EMENAR-region, allows our business to better match the overall geographic balance of the global rare-disease domain. The growth in both regions strengthens our commercial platform and adds to our financial capacity.
We continue to advance and expand our late-stage pipeline. With our ongoing investment in R&D, we are developing our existing therapies in-house and bringing in external late-stage candidate drugs that address significant unmet medical needs, create synergies in our portfolio, expand our global platform and show potential for future growth.